Medically reviewed by Doru Paul, MD Immunohistochemistry (IHC) is a special test used by pathologists to detect specific molecules on cells. It is widely used in clinical oncology for categorizing ...

Steven Hrycaj, PhD is the technical director of the Immunohistochemistry (IHC) Laboratory and co-director of the Rogel Cancer Center Tissue and Molecular Pathology (TMP) core at the University of ...

The global Immunohistochemistry Market is valued at an estimated USD 3.4 billion in 2024 and is projected to reach USD 5.2 ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Komen advocacy organization. HER2-ultralow is defined as immunohistochemistry (IHC) 0 with membrane staining. T-DXd, an antibody-drug conjugate now approved for multiple tumor types, gained ...

human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

FGFR2b, fibroblast growth factor receptor 2 isoform IIIb; H&E, hematoxylin and eosin; IHC, immunohistochemistry. Fig 3. Examples of FGFR2b IHC staining with different collection methods. H&E and ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.